INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04436679

Acronym

CaPaLong

Enrollment

342

Registered

2020-06-18

Start date

2021-02-02

Completion date

2025-02-22

Last updated

2025-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreas Cancer, Pancreatic Adenocarcinoma

Keywords

survival, prognosis, tissue, pancreas cancer

Brief summary

The study is particularly innovative as it will accurately analyze the microscopic characteristics of the stroma, tumor budding and mucin expression in adenocarcinomas of the pancreas, using a comparative approach of long-survivor/short-survival patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients \> 18 years of age at diagnosis * Primary pancreatic cancer patients operated on in one of the 4 centres between 2001 and 2016 * Histopathological diagnosis of excreto-pancreatic adenocarcinoma of the pancreas, ductal adenocarcinoma or classical adenocarcinoma * Tissue blocks (FFPE) available (tumour/healthy tissue) * Affiliated to a social security scheme

Exclusion criteria

* Absence of Primary Cancer Tissue Blocks (PCTBs) * Paraffin block fixed in Bouin or AFA * Patient Refusal * Pancreatic cancer not corresponding to a conventional excretopancreatic adenocarcinoma such as: carcinoma on intraductal papillary mucinous neoplasm, endocrine tumor/carcinoma, acinar cell carcinoma, ...). * Patient died due to post-surgical complications (death within 30 days post-surgery). * Surgical resection of macroscopic R2 type.

Design outcomes

Primary

Measure	Time frame	Description
Relationship between known prognostic histological markers of pancreatic adenocarcinoma and patient survival.	at 2 years	Tissue analysis will be performed by conventional microscopy and will evaluate histological markers known in the literature to have a prognostic impact.

Secondary

Measure	Time frame	Description
Relationship between newly described histological markers for pancreatic adenocarcinoma and patient survival.	at 2 years	Immunohistochemistry tissue analysis. It will allow the evaluation of newly described histological markers for pancreatic adenocarcinoma, which could have a prognostic impact such as the immunophenotype of the inflammatory infiltrate, the expression of the mucins MUC1, MUC5AC, MUC4, MUC16, mesothelin, p53, Ki67 (MIB1) and markers of aggressive subtypes identified by transcriptome studies, in particular the basal-like molecular subtype.

Countries

France

Outcome results